. Two clinically important cardiac drugs ouabain and digitalis, inhibit the Na+-K+-ATPase by binding to the extracellular domain. This enzyme can consume significant amounts of cellular ATP energy. The Na+-K+-ATPase can be coupled to various other transporters, such as those involved in transport of glucose (see later).